Original-Research: NanoRepro AG (von NuWays AG): BUY
|
Original-Research: NanoRepro AG - from NuWays AG
Classification of NuWays AG to NanoRepro AG
Nutritional elixirs as third consolidated pillar for NanoRepro On Tuesday, NanoRepro announced it acquired the remaining 67% of hyped about science GmbH, in which it previously held 33% as an equity stake. In detail: ALPHABIOL under a clearer structural umbrella. Going forward, the ALPHABIOL brand will sit in the now fully owned hyped about science GmbH, which is to be renamed ALPHABIOL GmbH. This gives NanoRepro a dedicated legal vehicle in which to develop its nutritional elixirs brand independently of the group's other activities and to position it as a distinct pillar of the business, on FY25 revenues of € 0.5m (eNuW) and an 8.6% CAGR through FY30 (eNuW). Transaction rationale. ALPHABIOL had been migrated out of NanoRepro into the hyped about science ecosystem in Q1 26 in order to be combined with a second luxury-oriented product (Phlas). The current step reverses that logic and separates the two brands again, allowing each to be run under a cleaner, independent strategy. NanoRepro acquired the remaining equity stake in hyped about science GmbH, which includes € 1.0m of capital held within the company, which includes the ALPHABIOL brand and products (eNuW: € 2.5m total value). For this, NanoRepro paid € 25k and transferred the Phlas brand and associated product to terraplasma GmbH (previous co-owner of hyped about science). Importantly, the terms imply no write-down of asset value at NanoRepro. Three consolidated pillars. NanoRepro will hence rest on three clearly defined pillars: rapid testing kits, PAEDIPROTECT and ALPHABIOL. These are complemented by the c. 44% stake in DKW (newkee) and an assumed mid- to high-single-digit stake in FibreSense (eNuW; figure not published). Reflecting the consolidation of hyped about science GmbH from FY26e, we now expect group sales of € 19m (up 18.7% yoy) and EBITDA of € -0.3m, a notably improvement compared to € -1.7m in FY25e (eNuW). Beyond the portfolio work, we expect management to keep its focus on scaling the multi-brand consumer health platform while extracting internal efficiencies, notably the finance and back-office harmonization planned from Q4 26 under incoming CFO Mike Eckel and the centralization of logistics in Kirchhain. In our view, this supports the expected lift in the EBITDA margin from -11% in FY25 (eNuW) to 5% in FY27e (eNuW). Maintaining BUY at a PT of € 4.40, based on DCF. You can download the research here: nanorepro-ag-2026-09-03-update-en-e1737 For additional information visit our website: https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||
2393056 03.09.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 16,93 | 162,72 | 38,49 | 3,18 | 4,47 | 16,00 | 18,00 | |
| EBITDA1,2 | 4,69 | 39,53 | 5,46 | -4,42 | -3,52 | -1,70 | 0,15 | |
| EBITDA-Margin3 | 27,70 | 24,29 | 14,19 | -138,99 | -78,75 | -10,63 | 0,83 | |
| EBIT1,4 | 2,80 | 38,81 | -4,37 | -5,34 | -3,62 | -2,80 | 0,05 | |
| EBIT-Margin5 | 16,54 | 23,85 | -11,35 | -167,93 | -80,98 | -17,50 | 0,28 | |
| Net Profit (Loss)1 | 1,70 | 29,72 | -3,72 | -4,69 | -2,05 | -2,00 | -0,03 | |
| Net-Margin6 | 10,04 | 18,27 | -9,67 | -147,48 | -45,86 | -12,50 | -0,17 | |
| Cashflow1,7 | -1,11 | 8,21 | 13,15 | -10,26 | 9,86 | -1,30 | -0,15 | |
| Earnings per share8 | 0,13 | 2,30 | -0,29 | -0,36 | -0,16 | -0,15 | -0,01 | |
| Dividend per share8 | 0,00 | 0,50 | 0,15 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PanTaxAudit
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| NanoRepro | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 657710 | DE0006577109 | AG | 25,27 Mio € | 14.10.2008 | Halten | 9F2CRQ59+3R |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 19,78 | 16,09 | 1,23 | -25,43 | 0,66 | 2,56 | 1,58 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 07.09.2026 | - | 31.10.2026 | - | 30.10.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -10,19% | +5,70% | +18,27% | +0,00% | -83,06% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
